ContemporAry ProspecTive Understanding of Migraine Real World Evidence Study
- Conditions
- G43Migraine
- Registration Number
- DRKS00030412
- Lead Sponsor
- AbbVie GmbH & Co. KG
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 1540
1. Patients able to give voluntary informed consent before starting any study related
assessments or procedures (to be obtained/documented as per local regulations)
2. Male or female participants age =18 at Visit 1
3. Diagnosis of migraine for at least one year at the discretion of the study investigator
according to ICHD criteria.
4. Age of the participant at the time of migraine onset < 50 years.
5. Currently taking, at the time of consent, at least one migraine medicationindicated for
migraine.
6. History of=4 headache (HA) days per month on average (ICHD criteria) in the 3 month prior to screening in the investigator's judgment
7. =4 headache (HA) days in the 30-day screening period per Headache Diary
1. History of migraine accompanied by diplopia or decreased level of consciousness or retinal migraine as defined by ICHD-3, 2018.
2. Current diagnosis of new persistent daily headache, hemiplegic migraine, trigeminal autonomic cephalgia (e.g., cluster headache), headache attributed to trauma or injury
to the head and/or neck, headache attributed cranial and/or cervical vascular disorder, headache attributed non-vascular disorder of the cranium, neck, eyes, ears, nose, sinuses, teeth, mouth or other facial or cervical structure, or trigeminal neuralgia, or painful cranial neuropathy as defined by ICHD-3, 2018.
3. In the opinion of the investigator, participant history or current evidence of any condition that might interfere with participant's ability to comply with the study requirements
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method